eBulletin Newsletter

NCCN Flash Updates: NCCN Templates Updated for Esophageal and Esophagogastric Junction Cancers

NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates^®) for Esophageal and Esophagogastric Junction Cancers to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Esophageal and Esophagogastric Junction Cancers v2.2023.

• The following templates have been deleted:
  • ESO23: Trastuzumab + Chemotherapy
  • ESO79: DOCEtaxel/CISplatin Weekly with Concurrent Radiation
• The following note has been updated in the Myeloid Growth Factor Therapy section for all templates with an Intermediate Febrile Neutropenia Risk:
  • G-CSFs may be considered for primary prophylaxis based on the febrile neutropenia (FN) risk of the chemotherapy regimen and patient risk factors. For more information on prophylaxis of FN and a list of appropriate agents, refer to the NCCN Guidelines for Hematopoietic Growth Factors and/or Appendix C to the NCCN Templates.
• The following NEW templates have been added:
  • ESO29a: mFOLFOX6 (Fluorouracil continuous infusion/Leucovorin/OXALIplatin) + Trastuzumab
  • ESO38a: DOCEtaxel/CISplatin/Fluorouracil + Trastuzumab
  • ESO39a: DOCEtaxel/OXALIplatin/Fluorouracil + Trastuzumab
  • ESO44a: CISplatin/Fluorouracil/Leucovorin + Trastuzumab
  • ESO45a: CISplatin/Capecitabine + Trastuzumab
  • ESO46a: OXALIplatin/Leucovorin/Fluorouracil + Trastuzumab
  • ESO48a: FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) + Trastuzumab
  • ESO50a: DOCEtaxel/CISplatin Every 21 Days + Trastuzumab
  • ESO51a: PACLitaxel/CISplatin Every 21 Days + Trastuzumab
  • ESO52a: PACLitaxel/CISplatin Every 14 Days + Trastuzumab
  • ESO53a: PACLitaxel/CARBOplatin Every 21 Days + Trastuzumab
  • ESO54a: Simplified Biweekly Infusional Fluorouracil/Leucovorin + Trastuzumab
  • ESO55a: Fluorouracil Continuous Infusion + Trastuzumab
  • ESO56a: Capecitabine + Trastuzumab
  • ESO57a: DOCEtaxel + Trastuzumab
  • ESO58a: PACLitaxel + Trastuzumab
  • ESO77a: CISplatin Day 1/Fluorouracil Days 1 – 4 + Trastuzumab
  • ESO84a: CapeOX (Capecitabine/OXALIplatin)  + Trastuzumab
  • ESO93a: Low Dose CapeOX (Capecitabine/OXALIplatin) + Trastuzumab
• Changes to the Indication section have been made to the following templates:
  • ESO17: CISplatin/Irinotecan
  • ESO29: mFOLFOX6 (Fluorouracil continuous infusion/Leucovorin/OXALIplatin)
  • ESO38: DOCEtaxel/CISplatin/Fluorouracil
  • ESO39: DOCEtaxel/OXALIplatin/Fluorouracil
  • ESO44: CISplatin/Fluorouracil/Leucovorin
  • ESO45: CISplatin/Capecitabine
  • ESO46: OXALIplatin/Leucovorin/Fluorouracil
  • ESO48: FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan)
  • ESO50: DOCEtaxel/CISplatin Every 21 Days
  • ESO51: PACLitaxel/CISplatin Every 21 Days
  • ESO52: PACLitaxel/CISplatin Every 14 Days
  • ESO53: PACLitaxel/CARBOplatin Every 21 Days
  • ESO54: Simplified Biweekly Infusional Fluorouracil/Leucovorin
  • ESO55: Fluorouracil Continuous Infusion
  • ESO56: Capecitabine
  • ESO57: DOCEtaxel
  • ESO58: PACLitaxel
  • ESO70: DOCEtaxel/Irinotecan
  • ESO71: Irinotecan
  • ESO72: DOCEtaxel/CISplatin with Concurrent Radiation
  • ESO77: CISplatin Day 1/Fluorouracil Days 1 – 4
  • ESO84: CapeOX (Capecitabine/OXALIplatin)
  • ESO89: Pembrolizumab
  • ESO91: Larotrectinib
  • ESO92: Entrectinib
  • ESO93: Low Dose CapeOX (Capecitabine/OXALIplatin)
  • ESO96: CapeOX (Capecitabine/OXALIplatin) + Pembrolizumab
  • ESO97: Capecitabine/CISplatin + Pembrolizumab
  • ESO98: CapeOX (Capecitabine/OXALIplatin) + Nivolumab
  • ESO99: CISplatin/Fluorouracil + Pembrolizumab
  • ESO100: mFOLFOX6 (Continuous Infusion Fluorouracil/Leucovorin/OXALIplatin) + Pembrolizumab
  • ESO101: mFOLFOX6 (Continuous Infusion
  • Fluorouracil/Leucovorin/OXALIplatin) + Nivolumab
  • ESO105: Dostarlimab-gxly
• Changes to the Chemotherapy Regimen section have been made to the following templates:
  • ESO29: mFOLFOX6 (Fluorouracil continuous infusion/Leucovorin/OXALIplatin)
  • ESO38: DOCEtaxel/CISplatin/Fluorouracil
  • ESO39: DOCEtaxel/OXALIplatin/Fluorouracil
  • ESO44: CISplatin/Fluorouracil/Leucovorin
  • ESO45: CISplatin/Capecitabine
  • ESO46: OXALIplatin/Leucovorin/Fluorouracil
  • ESO48: FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan)
  • ESO50: DOCEtaxel/CISplatin Every 21 Days
  • ESO51: PACLitaxel/CISplatin Every 21 Days
  • ESO52: PACLitaxel/CISplatin Every 14 Days
  • ESO53: PACLitaxel/CARBOplatin Every 21 Days
  • ESO54: Simplified Biweekly Infusional Fluorouracil/Leucovorin
  • ESO55: Fluorouracil Continuous Infusion
  • ESO56: Capecitabine
  • ESO57: DOCEtaxel
  • ESO58: PACLitaxel
  • ESO72: DOCEtaxel/CISplatin with Concurrent Radiation
  • ESO77: CISplatin Day 1/Fluorouracil Days 1 – 4
  • ESO84: CapeOX (Capecitabine/OXALIplatin)
  • ESO93: Low Dose CapeOX (Capecitabine/OXALIplatin)
  • ESO96: CapeOX (Capecitabine/OXALIplatin) + Pembrolizumab
  • ESO97: Capecitabine/CISplatin + Pembrolizumab
  • ESO98: CapeOX (Capecitabine/OXALIplatin) + Nivolumab
  • ESO99: CISplatin/Fluorouracil + Pembrolizumab
  • ESO100: mFOLFOX6 (Continuous Infusion Fluorouracil/Leucovorin/OXALIplatin) + Pembrolizumab
  • ESO101: mFOLFOX6 (Continuous Infusion Fluorouracil/Leucovorin/OXALIplatin) + Nivolumab
• Changes to the Emetic Risk have been made to the following templates:
  • ESO72: DOCEtaxel/CISplatin with Concurrent Radiation
  • ESO89: Pembrolizumab
  • ESO96: CapeOX (Capecitabine/OXALIplatin) + Pembrolizumab
  • ESO97: Capecitabine/CISplatin + Pembrolizumab
  • ESO98: CapeOX (Capecitabine/OXALIplatin) + Nivolumab
  • ESO99: CISplatin/Fluorouracil + Pembrolizumab
  • ESO101: mFOLFOX6 (Continuous Infusion Fluorouracil/Leucovorin/OXALIplatin) + Nivolumab
• References have been updated on the following templates:
  • ESO48: FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 
  • ESO72: DOCEtaxel/CISplatin with Concurrent Radiation
  • ESO80a: FOLFOX (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) with Concurrent Radiation
  • ESO94: FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) + Ramucirumab
  • ESO102: Irinotecan + Ramucirumab
  • ESO103: Fluorouracil Continuous Infusion/OXALIplatin with Concurrent Radiation
• Drug information notes for the following agents have been updated in the Supportive Care, Monitoring and Hold Parameters, and/or Safety Parameters and Special Instructions sections:
  • CISplatin
  • DOCEtaxel
  • Dostarlimab-gxly
  • Fam-trastuzumab deruxtecan-nxki
  • Nivolumab
  • OXALIplatin
  • PACLitaxel
  • Pembrolizumab
  • Ramucirumab

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium^®), the NCCN Biomarkers Compendium^®, the NCCN Chemotherapy Order Templates (NCCN Templates^®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients^®, please visit NCCN.org/patientguidelines.

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium^®, and other NCCN Content.

Subscribe to NCCN Flash Updates™

Third Party Content: The NCCN Content may contain content (such as figures, tables or illustrations) that NCCN licenses from third parties as displayed on NCCN Third Party Content site: https://private.filesanywhere.com/fs/v.aspx?v=8a6d65cfa19ea4bda0a3&C=6241. Licensee shall be solely responsible for obtaining permissions from each such third party to use any such Third Party Content in the Permitted Works. 

Access information on permissions and licensing of NCCN Content

Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.